Study design.

<p>Study design.</p

Specific IgG1 production and inhibition of enzymatic activity of rSh28GST by sera of vaccinated volunteers.

<p>Adult human volunteers received three administrations of rSh28GST of 100 µg respectively at D0, D28 and D150. IgG1 production is expressed as mean +/− SEM of titers at each time. Titer was defined as the highest dilution yielding an absorbance three times above background. Enzymatic inhibition is expressed in % (histograms). Percentage of inhibition was calculated by the ratio GST activity after serum incubation to GST activity control. This value was considered significantly positive above 10%.</p

Anti-Sh28GST antibody levels in healthy adult volunteers after administration of Alum (comparator group).

a<p>Specific Ig antibody levels are expressed as the mean of individual titer (± SEM). Number of responders after vaccination is indicated in parentheses.</p>b<p>Day of comparator administration (D₀; D₂₈; D₁₅₀).</p

Main baseline laboratory results.

<p>Abbreviations: WBC, white blood cell count; PTT, partial thromboplastin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase. Data are presented as mean ± standard deviation.</p>*<p>Local laboratory values. All other biological tests were in normal ranges.</p

Anti-Sh28GST antibody levels in healthy adult volunteers after administration of rSh28GST 100 µg.

a<p>Specific Ig antibody levels are expressed as the mean of individual titer (± SEM). Number of responders after vaccination is indicated in parentheses.</p>b<p>Day of Sh28GST administration (D₀; D₂₈; D₁₅₀).</p>*<p>Significantly different (P<0.05) compared to D₀ (comparison of mean using the Wilcoxon test).</p>**<p>Significantly different (P<0.05) compared to D₁₅₀ (comparison of mean using the Wilcoxon test).</p

Genotype/Phenotype Analyses for 53 Crohn’s Disease Associated Genetic Polymorphisms

<div><h3>Background & Aims</h3><p>Recent studies reported a role for more than 70 genes or loci in the susceptibility to Crohn’s disease (CD). However, the impact of these associations in clinical practice remains to be defined. The aim of the study was to analyse the relationship between genotypes and phenotypes for the main 53 CD-associated polymorphisms.</p> <h3>Method</h3><p>A cohort of 798 CD patients with a median follow up of 7 years was recruited by tertiary adult and paediatric gastroenterological centres. A detailed phenotypic description of the disease was recorded, including clinical presentation, response to treatments and complications. The participants were genotyped for 53 CD-associated variants previously reported in the literature and correlations with clinical sub-phenotypes were searched for. A replication cohort consisting of 722 CD patients was used to further explore the putative associations.</p> <h3>Results</h3><p>The <em>NOD2</em> rare variants were associated with an earlier age at diagnosis (p = 0.0001) and an ileal involvement (OR = 2.25[1.49–3.41] and 2.77 [1.71–4.50] for rs2066844 and rs2066847, respectively). Colonic lesions were positively associated with the risk alleles of <em>IL23R</em> rs11209026 (OR = 2.25 [1.13–4.51]) and 6q21 rs7746082 (OR = 1.60 [1.10–2.34] and negatively associated with the risk alleles of <em>IRGM</em> rs13361189 (OR = 0.29 [0.11–0.74]) and <em>DEFB1</em> rs11362 (OR = 0.50 [0.30–0.80]). The <em>ATG16L1</em> and <em>IRGM</em> variants were associated with a non-inflammatory behaviour (OR = 1.75 [1.22–2.53] and OR = 1.50 [1.04–2.16] respectively). However, these associations lost significance after multiple testing corrections. The protective effect of the <em>IRGM</em> risk allele on colonic lesions was the only association replicated in the second cohort (p = 0.03).</p> <h3>Conclusions</h3><p>It is not recommended to genotype the studied polymorphisms in routine practice.</p> </div

Time of the first non proctologic surgery according to IL23R rs11209026 genotype.

<p>Log Rank: P = 0.03.</p

Most significant results of the genotype/phenotype analyses obtained with the exploratory cohort.

<p>AZA = azathioprine. IFX = infliximab. NA: not applicable.</p

Main characteristics of the cohorts of Crohn’s Disease patients.

<p>Main characteristics of the cohorts of Crohn’s Disease patients.</p